Catalyst Wire Dossier Catalyst Wire Dossier

IDegAsp 50 (insulin degludec/insulin aspart)

insulin degludec/insulin aspart · Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IDegAsp 50 (insulin degludec/insulin aspart), covering 2016-01-15 to 2016-01-15. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects [Phase 1]

See pricing